To resect or not to resect?-the dilemma in oligometastatic breast cancer.
作者信息
Lonardi Sara, Guarneri Valentina
机构信息
Medical Oncology 3, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
出版信息
Hepatobiliary Surg Nutr. 2022 Aug;11(4):623-625. doi: 10.21037/hbsn-22-168.
Abstract
摘要
相似文献
1
To resect or not to resect?-the dilemma in oligometastatic breast cancer.
Hepatobiliary Surg Nutr. 2022 Aug;11(4):623-625. doi: 10.21037/hbsn-22-168.
2
Treatment Strategies for Oligometastatic Breast Cancer.
Curr Treat Options Oncol. 2021 Aug 23;22(10):94. doi: 10.1007/s11864-021-00889-2.
3
Oligometastatic breast cancer: Are we there yet?
Int J Cancer. 2021 Oct 15;149(8):1520-1528. doi: 10.1002/ijc.33693. Epub 2021 Jun 8.
4
Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Ann Palliat Med. 2021 May;10(5):5954-5968. doi: 10.21037/apm-20-1128. Epub 2020 Sep 10.
5
Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
Indian J Cancer. 2017 Jan-Mar;54(1):343-346. doi: 10.4103/ijc.IJC_152_17.
6
Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China.
Int J Cancer. 2020 Dec 1;147(11):3199-3205. doi: 10.1002/ijc.33152. Epub 2020 Jul 9.
7
Oligometastatic Breast Cancer.
Semin Radiat Oncol. 2022 Jul;32(3):282-290. doi: 10.1016/j.semradonc.2022.01.008.
8
Radiation therapy for oligometastatic bone disease in breast cancer.
Transl Cancer Res. 2020 Aug;9(8):5096-5101. doi: 10.21037/tcr.2020.01.35.
9
Clinical outcomes of the "resect and discard" strategy using magnifying narrow-band imaging for small (< 10 mm) colorectal polyps.
Endosc Int Open. 2018 Dec;6(12):E1382-E1389. doi: 10.1055/a-0650-4362. Epub 2018 Nov 21.
10
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer.
Crit Rev Oncol Hematol. 2018 Dec;132:154-160. doi: 10.1016/j.critrevonc.2018.10.001. Epub 2018 Oct 11.
引用本文的文献
1
Prognosis for local radical treatment in patients with esophageal squamous cell carcinoma with low-risk oligometastatic recurrence after curative resection: a retrospective cohort study.
J Gastrointest Oncol. 2024 Jun 30;15(3):807-817. doi: 10.21037/jgo-24-205. Epub 2024 Jun 17.
本文引用的文献
1
Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis.
Cancers (Basel). 2022 Mar 26;14(7):1691. doi: 10.3390/cancers14071691.
2
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663.
3
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
ESMO Open. 2022 Apr;7(2):100409. doi: 10.1016/j.esmoop.2022.100409. Epub 2022 Feb 26.
4
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19.
5
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
JCO Precis Oncol. 2021 Jul 21;5. doi: 10.1200/PO.21.00101. eCollection 2021 Jul.
6
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1.
7
Renewed considerations on the utility (or the futility) of hepatic resections for breast cancer liver metastases.
Hepatobiliary Surg Nutr. 2021 Jan;10(1):49-58. doi: 10.21037/hbsn.2019.07.12.
8
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23.
9
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Ann Oncol. 2020 Nov;31(11):1526-1535. doi: 10.1016/j.annonc.2020.08.2098. Epub 2020 Aug 20.
10
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
Zotero 插件